Shockwave Medical has announced the closing of US$45 million in Series C financing led by Sectoral Asset Management, with participation from mutual funds advised by T Rowe Price Associates and returning investors including Sofinnova Partners, Venrock, RA Capital, Deerfield, Ally Bridge Group and others.
Spectranetics’ Stellarex 0.014” drug-coated angioplasty balloon has received the CE mark.
Clinical data presented at the 2016 VEITH symposium (New York City, USA) of the global Ovation Pivotal Trial has revealed positive five-year safety and effectiveness for the Endologix Ovation system.
LimFlow has received CE mark for its fully percutaneous LimFlow system designed for venous arterialisation of the lower limbs in end-stage patients at risk of limb amputation for critical limb ischaemia.
Gore joined with leaders across the vascular and endovascular community in honouring five North American physicians as Pioneers in Performance. The biennial awards programme acknowledges exceptional work in the field of vascular and endovascular therapy, including aortic and lower limb bypass and dialysis access surgery.
Lombard Medical has announced that its Altura endovascular stent graft system was featured in a scientific presentation at the VEITHsymposium in New York, USA, on 17 November 2016. The Altura stent graft, which was launched commercially in Europe earlier in 2016, is specifically designed to simplify treatment in patients with normal abdominal aortic aneurysm anatomy.
Aortica Corporation has announced that Benjamin Starnes, chief of Vascular Surgery at the University of Washington, completed the first three-vessel fenestrated endovascular aneurysm repair (FEVAR) using Aortica’s AortaFit investigational automated case planning software and Bolton Medical’s Treo abdominal stent graft system as part of his physician-sponsored IDE study.
Data from Endologix’ Global Registry have found 98% freedom from persistent endoleaks with its Nellix system at two-year follow-up, among other positive results. The patient cohort—of which over one-third exhibited complex anatomies—also experienced strong aneurysm and cardiovascular-related mortality results and zero secondary interventions for Type II endoleaks.
Medtronic has announced data demonstrating that the company’s Heli-FX EndoAnchor system enhances outcomes and durability in patients with complex aortic abdominal aneurysm (AAA) anatomy, particularly those who have hostile aortic neck anatomy.
Teleflex’ Arrow Vascular positioning system (VPS) Rhythm device with optional TipTracker technology has been issued 510(k) clearance from the US Food and Drug Administration (FDA) to commercialise the device in the USA.
The MAJESTIC trial set out to evaluate the performance of the Eluvia paclitaxel-eluting vascular stent system (Boston Scientific) in the treatment of femoropopliteal artery lesions. Two-year results show a greater than 90% freedom from target lesion revascularisation rate.
A preliminary analysis suggests that thermal ablation may be effective in selected patients with local small cell lung cancer without adjuvant therapy. The research from Brown University, Providence, USA was published in the Journal of Vascular and Interventional Radiology (JVIR).
Liver cancer researchers from France and Singapore collaborate on a prospective meta-analysis of two studies of Y-90 resin microspheres vs. sorafenib in patients with unresectable hepatocellular carcinoma.
A new study presented at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE 2016, 10–14 September, Barcelona, Spain) meeting finds that the treatment of prostate cancer with irreversible electroporation is efficacious and safe.
On 17 August, a multicentre, randomised, double-blind, placebo-controlled trial—the VAPOUR trial—was published online ahead of print in The Lancet. Six-month data from the trial provide the first sham-controlled evidence in support of using the procedure.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos